A single center experience: post-transplantation adjuvant chemotherapy impacts the prognosis of hepatocellular carcinoma patients

Background The aim of this research was to investigate the impact of post-transplantation adjuvant chemotherapy in the prevention of tumor recurrence and metastasis for hepatocellular carcinoma （HCC） exceeding Milan criteria after liver transplantation.Methods A total of 117 patients with HCC exceeding the Milan criteria who had undergone orthotopic liver transplantation （OLT） from August 2002 to February 2009 were enrolled and retrospectively analyzed.The patients were divided into four groups according to chemotherapy regimens and the impact of different chemotherapy regimens on survival,disease-free survival,and adverse effects were compared.Results One year survival rates for the gemicitabine,conventional chemotherapy,oxaliplatin plus capecitabine and the best supportive care （BSC） group were 87.5％,84.2％,81.6％,and 67.5％.The 3-year survival rates were 48.1％,25.9％,31.6％,and 33.7％,respectively for the four groups.One year disease free survival rates for the four groups were 69.8％,47.4％,53.8％,and 45.7％ respectively.And 3-year disease free survival rates were 43.2％,23.7％,23.6％,and 25.1％ for the four groups.Stratification analysis showed that the gemcitabine regimen and conventional chemotherapy could significantly improve the survival rate and disease free survival rate for HCC patients who had major vascular invasion and/or microvascular invasion after liver transplantation compared with BSC group.Conclusions For HCC patients beyond Milan criteria,especially who had vascular invasion and/or micorvascular invasion,post-transplantation adjuvant chemotherapy can significantly improve survival.Gemcitabine is a proper regimen for postoperative adjuvant chemotherapy.Conventional chemotherapy can also benefit patients,but the adverse effects are not satisfactory.     

Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

Background Accumulating evidence indicates that systemic inflammation response is associated with the prognosis of various cancers. The aim of this study was to investigate the neutrophil-lymphocyte ratio (NLR), which is one of the systemic inflammation markers, in the prognosis of hepatocellular carcinoma (HCC) after treatment of transcatheter arterial chemoembolization (TACE).

Methods The clinical data of 178 HCC patients who received TACE were retrospectively analyzed. The optimal NLR cutoff was determined according to the receiver operating characteristic (ROC) analysis. All patients were divided into NLR-normal group and NLR-elevated group according to the cutoff, and the clinical features of these two groups were comparatively analyzed. Meanwhile, the overall survival and disease free survival (DFS) were analyzed using the Kaplan-Meier method. The risk factors of postoperative survival were investigated using univariate and multivariate Cox regression analyses.

Results The optimal NLR cutoff was defined at 1.85 and 42 (23.6%) patients had an elevated NLR (NLR>1.85). The median survival time was 9.5 months (range 1–99 months). The clinical data between the two groups were comparable, except for α-fetoprotein. Follow-up results showed that the median survival of patients with normal NLR was 17.5 months (range: 1–99 months) compared with 8 months (range: 8–68 months) of patients with elevated NLR. The 1, 3 and 5-year overall survival of patients in the NLR-normal group and NLR-elevated group were 57.3%, 44.1%, and 27.2% and 42.1%, 19.6%, and 9.5% respectively (χ2=194.2, P <0.001). Similarly, the disease free survival also has a significant difference (χ2=39.3, P <0.001). Multivariate Cox regression analysis showed that a high NLR was an independent factor affecting the survival rate of HCC after TACE (P=0.04).

Conclusion Preoperative NLR was an important prognostic factor to predict the prognosis of patients with intermediate HCC treated with TACE.

     

18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer

Background The outcome of surgical treatment of non-small-cell lung cancer （NSCLC） remains poor. In many patients the biological behavior of NSCLC does not follow a definite pattern, and can not be accurately predicted before treatment. ^18F-fluoro-2-deoxy-glucose （^18F-FDG） uptake on positron-emission tomography （PET） is associated with the aggressiveness of NSCLC. The present study focused on the role of ^18F-FDG uptake in predicting the outcome of surgically treated patients with NSCLC. Methods A retrospective analysis was made of 82 patients who underwent complete resection and preoperative FDG PET. The maximum standardized uptake value （SUVmax）, in addition to five clinicopathological factors and three biomolecular factors, which could possibly influence survival, was compared for possible association with patients＇ recurrence and survival, by the Log-rank test in univariate analysis and the Cox proportional hazards model in multivariate analysis. The association between SUVmax and other factors was also analyzed. Results Patients with SUVmax more than 11 had a disease-free survival and overall survival shorter than patients with SUVmax less than 11 in univariate analyses （P〈0.001, P=0.002）. In the multivariate analysis, SUVmax （dichotomized by 11） was the only significant predictor for tumor recurrence. TNM stage and SUVmax （dichotomized by 11） were independent predictors for the overall survival. Associations of SUVmax with p53 overexpression, proliferating cell nuclear antigen （PCNA） labeling index and microvascular density of the tumor were significant in the entire group. Conclusions ^18F-FDG uptake on PET may be used to noninvasively assess biological aggressiveness of NSCLC in vivo, identifying the surgically-treated patients with poor prognosis who could benefit from additional therapy.     

Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma

Background Transarterial chemoembolization （TACE） is the most widely used primary treatment for unresectable hepatocellular carcinoma （HCC） due to its survival benefit, though its clinical effect is still far from satisfactory. Jiedufang （JDF） granule preparation is a commonly used Chinese herbal medicine formula for HCC. The aim of this study was to evaluate the effect of combined therapy with TACE and JDF granule preparation in treatment of unresectable HCC on survival. Methods A retrospective study of TACE was performed in 165 patients with unresectable HCC who were admitted between January 2002 and December 2007 in Changhai Hospital, Shanghai, China. Of the 165 patients, 80 patients （study group） received combined therapy consisting of TACE and a long-term maintenance treatment with oral JDF granule preparation, and the remaining 85 patients （control group） received TACE alone. The survival rates of both groups were calculated by the Kaplan-Meier method. Factors possibly affecting survival were assessed by multivariate analysis in the Cox proportional hazard model, such as maximum tumor size, number of lesions, portal vein invasion, and etc. Results The median overall survival was 9.2 months （95% CI： 6.94-11.46） in the study group versus 5.87 months （95% CI： 4.21-7.52） in the control group. In the study group,survival rates of the 1-, 2- and 3-year follow-up were 41.2%, 18.4%, and 9.6%, respectively. Significant independent prognostic factors identified by the Cox regression analysis were as follows： serum hepatitis B surface antigen （HBsAg） （P=0.014）, maximum tumor size （P=0.027）, number of lesions （P 〈0.001）, portal vein invasion （P 〈0.001）, and the therapy model （P=-0.006）. Conclusion Combination therapy of TACE and JDF granule preparation may significantly prolong survival of patients with unresectable HCC.     

前入路右半肝切除术与传统右半肝切除术治疗大肝癌的对比观察

Objective To compare the outcomes between anterior versus conventional approach right hepatectomy for large hepatocellutar carcinoma(HCC).Methods A total of 188 consecutive patients with large HCC(≥5 cm)undergoing right hepatectomy were reviewed retrospectively.Among them,92patients received anterior approach right hepatectomy(anterior group)while the other conventional right hepatectomy(conventional group).Their clinicopathologic data and survivals were compared.Results There were five surgical deaths(2.7%),two in the anterior group and three in the conventional group.The biochemical and tumor pathological data(except for tumor size) of these two groups were comparable.The mean intranperative blood loss,the number of patients with massive hemorrhage(＞3000ml)and the volume of blood transfusion of the anterior group were markedly less than those of conventional group.The 1-,3-year disease-free survival rates of the anterior group were significantly better than those of the conventional group anterior group were also markedly higher than those of conventional group.The Cox regression model indicated that tumor size[P=0.014,odd ratio(OD):1.074] and surgical procedure(P:0.009,OD=0.468) were independent risk factors correlated with disease-free survival.And the surgical procedure(P=0.003,OD=0.369) was the only independent risk factor for postoperative cumulative survival.Conclusion Anterior approach right hepatectomy can significantly decrease intraoperative blood loss.The postoperative survivals of large HCC patients are significantly improved by anterior approach right hepatectomy.     

前入路右半肝切除术与传统右半肝切除术治疗大肝癌的对比观察

Objective To compare the outcomes between anterior versus conventional approach right hepatectomy for large hepatocellutar carcinoma(HCC).Methods A total of 188 consecutive patients with large HCC(≥5 cm)undergoing right hepatectomy were reviewed retrospectively.Among them,92patients received anterior approach right hepatectomy(anterior group)while the other conventional right hepatectomy(conventional group).Their clinicopathologic data and survivals were compared.Results There were five surgical deaths(2.7%),two in the anterior group and three in the conventional group.The biochemical and tumor pathological data(except for tumor size) of these two groups were comparable.The mean intranperative blood loss,the number of patients with massive hemorrhage(＞3000ml)and the volume of blood transfusion of the anterior group were markedly less than those of conventional group.The 1-,3-year disease-free survival rates of the anterior group were significantly better than those of the conventional group anterior group were also markedly higher than those of conventional group.The Cox regression model indicated that tumor size[P=0.014,odd ratio(OD):1.074] and surgical procedure(P:0.009,OD=0.468) were independent risk factors correlated with disease-free survival.And the surgical procedure(P=0.003,OD=0.369) was the only independent risk factor for postoperative cumulative survival.Conclusion Anterior approach right hepatectomy can significantly decrease intraoperative blood loss.The postoperative survivals of large HCC patients are significantly improved by anterior approach right hepatectomy.     

Effects of diabetes mellitus on prognosis of the patients with colorectal cancer undergoing resection: a cohort study with 945 patients

Background Diabetes mellitus plays an important role in cancer prevalence and outcomes. The aim of this study was to evaluate the influence of DM on stages and outcomes among patients with colorectal cancer.Methods The study enrolled 945 patients who were diagnosed as having colorectal carcinoma from August 1994 to December 2002. In the cohort, 26 patients were diagnosed as having DM. With a median follow-up of 45.8 months,differences in overall survival and disease-free survival between the diabetes and non-diabetes groups were analyzed.Results Kaplan and Meier analysis showed that there were no significant differences between the two groups in overall survival rates at 3 years or 5 years. At 5 years, patients with DM, compared with patients without diabetes, experienced a significantly lower disease-free survival rate （34.2% diabetics vs. 55.1% non-diabetics; P=0.025）.Conclusions DM was associated with an increased risk of recurrence in patients with colorectal cancer.     

Clinical and pathological studies of borderline gastrointestinal stromal tumors

Background Borderline gastrointestinal stromal tumors （GISTs） are intermediate tumors between benign and malignant variants; however, the clinical and pathological features of borderline GISTs remain poorly defined. This study aimed to characterize GISTs and to identify a set of borderline criteria for practical use. Methods Medical records and specimens of 840 patients from 12 hospitals were retrospectively examined. Totally 485 and 76 patients with any of the parameters predictive of either malignant or benign tumors were excluded. The Kaplan-Meier method was used to calculate disease-free survival and overall survival rates. Results Among the remaining 279 borderline GIST patients, 223 were followed up for 1 to 31.48 years. Two patients developed local recurrence, and both were cured by subsequent operations alone. The 5-year disease-free survival and overall survival rates were 99% and 100%, respectively. Morphologically, borderline GISTs typically exhibited moderate cellularity, and subsets of them also showed moderate atypia, low mitotic activities, or large tumor size. According to the National Institutes of Health （NIH） consensus criteria, the risk levels of the 279 GISTs were classified to be very low to high. However, the disease-free survival rates were not significantly different among these risk groups （P=0.681）. Conclusions The proposed borderline GIST criteria in the current study may complement the existing NIH criteria, based primarily on tumor size and mitotic count, in the evaluation of the biological behaviors of GISTs. Since a subset of borderline GISTs with high risk level showed favorable outcome, the introduction of the borderline GIST system may avoid overdiagnosis and over therapy.     

Chinese Medicine Herbal Treatment Based on Syndrome Differentiation Improves the Overall Survival of Patients with Unresectable Hepatocellular Carcinoma

Objective:To investigate the effects of Chinese medicine(CM) herbal treatment based on syndrome differentiation on patients with unresectable hepatocellular carcinoma(HCC).Methods:A total of 94 patients with unresectable HCC were reviewed between June 2008 and June 2011.Survival analysis was performed between patients who received CM with/without non-curative antitumor treatments of Western medicine(WM)(CM group,30cases) and patients who were not treated with CM but with non-curative antitumor treatments of WM or supportive treatment alone(non-CM group,64 cases).Then,survival analysis was performed between patients treated with CM combined with non-curative antitumor treatments of WM(combination therapy group,25 cases) and patients with non-curative antitumor treatments of WM alone(non-curative antitumor treatments group of WM,52 cases).The survival analysis was performed by Kaplan-Meier method and prognostic factors for overall survival(OS) were assessed by the Cox proportional hazards regression model.Results:The median survival time(MST),1- and 2-year survival rates of the CM group and the non-CM group were 36 months,76.7%,56.1%and 12 months,48.4%,26.6%,respectively.The Log-rank test revealed significant difference between the two groups in OS(P<0.01).Cox proportional multivariate analysis revealed that CM was an independent favorable prognostic factor for OS.The MST,1- and 2-year survival rates of combination therapy group and non-curative antitumor treatments group of WM were 36 months,76.0%,55.5%and 13 months,55.8%,30.8%,respectively.There was significant difference in OS between the two groups(P=0.004).Conclusions:CM herbs based on syndrome differentiation have positive effects on survival of patients with unresectable HCC.Furthermore,combination therapy of CM and WM are recommended in HCC treatment.     

Both the 5th and 6th Editions of TNM Staging System Fail to Independently Predict Long-term Prognosis after Radical Hepatectomy in Hepatocellular Carcinoma Sized 〉 or = 5 cm

Objective To validate the predictive power of the 5th and 6th editions of TNM staging system （TNM-5, TNM-6） in a Chinese patient cohort with hepatocellular carcinoma （HCC） sized 〉 or = 5 cm after radical hepatectomy. Methods Consecutive 121 patients with HCC sized 〉 or = 5 cm undergoing radical hepatectomy between January 1995 and December 2002 were included. The impact of clinicopathological variables on prognosis was determined by univariate and multivariate analyses, after excluding 2 perioperative deaths. Results In univariate analysis, TNM-5 stage did not show prognostic significance for overall or disease-free survival, as opposed to TNM-6 stage, Edmondson-Steiner grade, portal vein tumor thrombosis （PVTT）, vascular invasion, satellite nodule, Child-Pugh grade, and hepatitis B surface antigen （HBsAg） positivity. When these significant variables were entered in multivariate analysis, Edmondson-Steiner grade was the sole independent prognosticator for both overall and disease-free survival, whereas Child-Pugh grade independently influenced disease-free survival. However, TNM-6 stage lost its predictive potential in multivariate analysis. Conclusions Neither TNM-5 nor TNM-6 staging system is revealed to be independently prognostic in patients with HCC sized 〉 or = 5 cm after radical hepatectomy. Therefore, TNM-6 calls for more support in many subsets of HCC patients.     

术前外周血中性/淋巴细胞比值对肝癌患者预后的影响

【目的】 评价肝癌患者术前外周血中性/淋巴细胞比值(NLR)对肝癌患者预后的影响及预测价值。【方法】 回顾性分析中山大学附属第五医院82例肝癌行肝部分切除患者临床病理资料,根据患者术前外周静脉血NLR大小分为低NLR 组(NLR < 5)和高NLR 组(NLR ≥ 5),Log rank单因素分析两组患者临床病理因素与无瘤生存时间、总生存时间之间的关系,将有统计学意义的单因素导入Cox回归模型进行风险分析。【结果】 所有患者1、3、5年总生存率分别为91.4%、66.5%、57.2%,其中高NLR组1、3、5年生存率分别为80.0%、51.9%、37.0%,低NLR组1、3、5年生存率分别为94.0%、69.7%、61.7%,差异有统计学意义(P = 0.044),1、3、5年无瘤生存率分别为87.4%、59.1%、49.7%,其中高NLR组1、3、5年无瘤生存率分别为80.0%、40.0%、26.7%,低1、3、5年NLR组生存率分别为89.1%、63.7%、55.3%,差异有统计学意义(P = 0.031)。单因素分析显示术前AFP ≥ 400 g/L,肿瘤最大径>5 cm,肿瘤数目 > 3个,NLR≥5,血管侵犯及切缘阳性是影响肝部分切除术后肝癌无瘤生存及总生存时间的危险因素,Cox回归分析提示术前NLR ≥ 5,肿瘤数目>3个以及最大肿瘤直径 > 5 cm及切缘阳性是肝癌复发的独立危险因素(P < 0.01)。【结论】 术前高NLR是影响肝癌患者术后复发的单独危险因素,对肝癌患者的预后有预测价值。     

围手术期抑瘤治疗对于进展期肝癌肝移植的临床价值

目的 探讨围手术期抑瘤治疗对降低进展期肝癌(pTNM分期:Ⅲ、Ⅳa)肝移植术后肝癌复发率、提高患者生存率的临床价值.方法 回顾分析了2002年4月至2005年12月于我院接受肝移植的36例Ⅲ、Ⅳa期肝癌患者的临床资料.抑瘤组患者(20例)术前均接受经皮肝动脉栓塞化疗(TACE)、或TACE联合射频消融(RFA)、无水酒精瘤内注射(PEI),术中、术后均采用阿霉素 5-氟尿嘧啶 顺铂方案行全身静脉化疗;以未接受任何抑瘤治疗的16例患者为对照(非抑瘤组),比较两组的肿瘤复发率、累计生存率和无瘤生存率.结果 抑瘤组肿瘤复发率(12/20,60.0%)明显低于非抑瘤组(14/16,87.5%)(P＜0.05).抑瘤组和非抑瘤组1年、2年生存率比较差异有显著意义(P＜0.05);抑瘤组1年、2年无瘤生存率亦显著高于非抑瘤组(P＜0.05).术前接受TACE联合RFA/PEI治疗的患者肿瘤坏死范围明显优于单用TACE者.结论 对于进展期肝癌患者等待肝移植期间采取TACE RFA/PEI治疗以抑制肿瘤进展,术后配合全身辅助化疗可以显著提高患者生存率、降低肿瘤复发率.阿霉素 5-氟尿嘧啶 顺铂化疗方案安全可行,具有临床应用价值.     

影响肝癌肝移植预后的高危因素分析及诊治经验

目的分析影响肝癌肝移植预后的临床病理因素,总结临床诊治经验.方法对198例肝癌肝移植患者临床病理特征进行生存率、无瘤生存率的比较（单因素分析）,并通过Cox多因素分析得到有独立意义的预后指标.结果198例肝癌肝移植患者0.5年、1年、2年生存率为89%、78%、65%,无瘤生存率为85%、73%、67%.单因素分析提示肿瘤大小、肿瘤侵犯血管程度、病理Edmondson分级、TNM分期、术前甲胎蛋白（AFP）影响患者无瘤生存率,并且前四个因素与患者生存率相关.Cox多因素分析示肿瘤侵犯血管是影响患者生存和肿瘤复发的独立因素.结论肿瘤侵犯血管是影响肝癌肝移植患者预后的重要因素,术前如何筛选出已有微小转移灶的患者以及如何在移植后预防肿瘤复发是肝癌肝移植发展的重要方向.     

微血管侵犯对肝细胞癌肝移植术后预后的影响

目的:探讨微血管侵犯（microvascular invasion,MVI）对肝细胞癌（HCC）肝移植术后预后的影响。方法:回顾性分析HCC行原位肝移植手术病人183例的临床和随访资料,其中符合米兰标准76例,USCF标准84例,上海标准102例,杭州标准126例。用Kaplan-Meier法计算4组1年、3年、5年累积生存率,并用Log-Rank检验比较各组生存曲线的差异。将每组分为MVI和无MVI亚组,比较肿瘤复发率、5年无瘤生存率及1年、3年、5年生存率。结果:4组病人的生存时间差异均无统计学意义（P>0.05）;随着HCC肝移植标准扩大,MVI率逐渐升高（P<0.05）,3年、5年生存率和5年无瘤生存率均逐渐降低（P<0.05）。符合上海标准病人中,无MVI亚组肿瘤复发率低于MVI亚组（P<0.05）,5年生存率和5年无瘤生存率均高于MVI亚组（P<0.05）;符合杭州标准病人中,无MVI亚组肿瘤复发率低于MVI亚组（P<0.05）,3年、5年生存率和5年无瘤生存率均高于MVI亚组（P<0.05~P<0.01）。结论:MVI可预测符合上海标准和杭州标准的HCC肝移植术后复发情况,对肝移植综合治疗具有指导意义。     

单中心连续203例肝移植临床疗效分析

目的探讨进一步提高肝移植疗效的措施。方法回顾性分析复旦大学附属中山医院2001年4月至2004年10月连续203例肝移植的临床资料。肝移植患者包括肝细胞癌142例、肝炎后肝硬化36例、暴发性肝功能衰竭7例、Wilson病6例以及其他终末期肝脏疾病12例。其中,尸体供肝移植199例,包括2例减体积肝移植、1例劈裂式肝移植;活体供肝移植4例。采用Cox多元回归分析确定影响肝癌肝移植预后的危险因素。结果203例肝移植患者术后1年、2年生存率分别为85．0％和82.4％。总的排斥反应发生率为12．3％。142例肝癌肝移植患者中有20例复发(复发率14.1％),1年、2年生存率分别为80.2％和78,4％,1年、2年无瘤生存率分别为85．3％和80．3％。多元回归分析显示肿瘤直径和门静脉癌栓是影响无瘤生存率的独立预后因素。结论肝移植是我国治疗各种终末期肝脏疾病的有效手段,同时可使部分肝癌患者获得治愈或延长生命的机会。     

Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China

Hepatocellularcarcinoma(HCC)asacommoncancerworldwidehasadismalprognosiswithamedianlifeexpectancyof6 to9 months 1 　Morethan 80% ofpatientswithHCChaveunderlyingcirrhosis, andofthesepatients, only10% to15% arepotentiallypossiblefortumorresection 2, 3　Therestareunsuitablefortumorresectionbecauseofsize, locationorseverityofunderlyingliverdisease Incirrhoticpatientswithoutlocalordistantmetastasis, orthotopiclivertransplantation(OLT) probablyoffersthebestchanceoflong termsurvival, sinceittreat…     

Correlative analysis between clinical stage of hepatocellular carcinoma and disease-free survival after hepatectomy

Nowhepatectomyisstillthefirstchoiceoftreatmentforprimaryhepaticcancer(PHC),butthehigherrecurrencelowersseriouslythelong-termresultsafterhepatectomy-Somedomesticpa-persreportedthatthe5-yeardisease-freesurvivalrateswere27.7%~48.6%L"'].Someabroadpa-persdescribedthe5-yearsurvivalrateswere25.6%~32.9%[s'`],anditisevidentthattheirdis-ease-freesurvivalrateswerefurtherlower-With`.lncreas1ngofmedicaltechnoIogyandstrengtheningofconsciousnessofhealthcare,somepatientshadtumorsdiscoveredinearlystageandrec…     

小肝癌患者微血管侵犯与肝移植后肿瘤复发及预后相关性研究

目的：分析影像学上符合Milan标准的肝癌肝移植患者术后复发相关的危险因素,评估Milan标准和微血管侵犯对肝移植术后肿瘤复发的预测价值。方法：回顾性分析浙江大学医学院附属第一医院2007—2013年期间115例影像学符合Milan标准并行肝移植治疗的肝癌患者,通过单因素及多因素Cox回归分析和生存分析探究影响肝移植术后肿瘤复发的危险因素,并分析其预测价值。结果：入组的98（98/115）例患者中,术后1、3、5年总体生存率及无瘤生存率分别为91.8%、80.6%、79.6%和87.8%、74.5%、73.5%。微血管侵犯、大血管侵犯、超出Milan标准和移植前降期治疗与小肝癌肝移植术后复发显著相关（P<0.05）;多因素分析提示微血管侵犯和超出Milan标准是预测肝癌肝移植术后复发的独立危险因素。肝癌不伴和伴有微血管侵犯的术后1、3、5年无瘤生存率分别为 92.8%、85.5%、85.5% 和75.9%、55.2%、48.3% （P<0.01）;而术后病理检查证实符合及超出Milan标准肝癌患者术后1、3、5年无瘤生存率分别为 91.7%、83.3%、79.8% 和 64.3%、42.9%、42.9% （P<0.01）。结论：微血管侵犯多提示肝癌肝移植受者术后肿瘤的高复发转移倾向,对指导术后早期积极的辅助治疗、密切随访及补救性治疗等都具有一定的临床意义。     

手术治疗无肝硬化肝癌患者87例预后分析

目的:探讨手术治疗无肝硬化肝癌患者预后的影响因素。方法:回顾性分析87例未合并肝硬化的肝癌切除术患者的临床病理资料,收集患者年龄、性别、术前HbsAg、白蛋白、甲胎蛋白(alpha-fetoprotein,AFP)等,以及术后病理诊断、术中术后输血量、TNM分期、肿瘤大小、住院天数、并发症,随访患者术后存活时间。单因素和多因素分析影响患者术后总生存时间、无瘤生存时间的因素。结果:本组患者住院期间死亡率为1.1%;1、3、5年总生存率分别为73.7%、45.2%、39.3%。1、3、5年无瘤生存率分别为61.5%、46.4%、31.9%。单因素分析和多因素分析提示,微血管浸润是影响患者术后无瘤生存时间和总生存时间的独立因素。结论:对于无肝硬化的肝癌患者,微血管浸润可以作为推测患者预后的独立因素。     

大肝细胞癌切除术后预后的相关因素分析

目的探讨影响大肝癌（直径≥5 cm且〈10 cm）根治术后生存的预后因素。方法对行手术切除获得随访的170例大肝癌患者的性别、年龄、血清HBs Ag等相关因素进行分析。用寿命表法计算肝癌术后1、3、5年总生存率和无瘤生存率,生存分析采用Kaplan-Meier法,采用Log-rank方法对相关因素进行单因素分析,采用Cox模型进行多因素分析。结果大肝癌术后1、3、5年生存率分别为74.6%、48.2%、35.8%,单因素分析结果提示术前甲胎蛋白（AFP）、门脉癌栓及术后复发是影响大肝癌术后总生存的预后因素（P〈0.05）;多因素分析提示门脉癌栓及术后复发是影响手术后总生存的独立危险因素（P〈0.05）。结论术前AFP、门脉癌栓及术后复发是影响大肝癌术后总生存率的预后因素;门脉癌栓及术后复发是影响手术后总生存的独立危险因素。